These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

666 related articles for article (PubMed ID: 38029929)

  • 1. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight and Cardiometabolic Parameters in Individuals With Obesity and Without Diabetes: A Systematic Review and Meta-Analysis.
    Ansari HUH; Qazi SU; Sajid F; Altaf Z; Ghazanfar S; Naveed N; Ashfaq AS; Siddiqui AH; Iqbal H; Qazi S
    Endocr Pract; 2024 Feb; 30(2):160-171. PubMed ID: 38029929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.
    Iqbal J; Wu HX; Hu N; Zhou YH; Li L; Xiao F; Wang T; Jiang HL; Xu SN; Huang BL; Zhou HD
    Obes Rev; 2022 Jun; 23(6):e13435. PubMed ID: 35194917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
    Yao H; Zhang A; Li D; Wu Y; Wang CZ; Wan JY; Yuan CS
    BMJ; 2024 Jan; 384():e076410. PubMed ID: 38286487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: A network meta-analysis of randomized clinical trials.
    Alkhezi OS; Alahmed AA; Alfayez OM; Alzuman OA; Almutairi AR; Almohammed OA
    Obes Rev; 2023 Mar; 24(3):e13543. PubMed ID: 36579723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
    Huang YN; Liao WL; Huang JY; Lin YJ; Yang SF; Huang CC; Wang CH; Su PH
    Diabetes Obes Metab; 2024 Nov; 26(11):5222-5232. PubMed ID: 39171569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T; Avgerinos I; Liakos A; Del Prato S; Matthews DR; Tsapas A; Bekiari E
    Diabetologia; 2022 Aug; 65(8):1251-1261. PubMed ID: 35579691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
    Herrou J; Mabilleau G; Lecerf JM; Thomas T; Biver E; Paccou J
    Calcif Tissue Int; 2024 Feb; 114(2):86-97. PubMed ID: 37999750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T; Christensen M; Junker AE; Knop FK; Gluud LL
    BMJ; 2012 Jan; 344():d7771. PubMed ID: 22236411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients.
    Ali S; Baig S; Wanninayake S; da Silva Xavier G; Dawson C; Paisey R; Geberhiwot T
    Diabetes Obes Metab; 2024 Mar; 26(3):989-996. PubMed ID: 38151964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of long-acting versus short-acting glucagon-like peptide-1 receptor agonists on improving body weight and related metabolic parameters in type 2 diabetes: A head-to-head meta-analysis.
    Yuan X; Gao Z; Hao Z; Ma H; Duan K; Yang C
    Medicine (Baltimore); 2023 Oct; 102(43):e35739. PubMed ID: 37904378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 Agonist to Treat Obesity and Prevent Cardiovascular Disease: What Have We Achieved so Far?
    Pedrosa MR; Franco DR; Gieremek HW; Vidal CM; Bronzeri F; de Cassia Rocha A; de Carvalho Cara LG; Fogo SL; Eliaschewitz FG
    Curr Atheroscler Rep; 2022 Nov; 24(11):867-884. PubMed ID: 36044100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials.
    Austregésilo de Athayde De Hollanda Morais B; Martins Prizão V; de Moura de Souza M; Ximenes Mendes B; Rodrigues Defante ML; Cosendey Martins O; Rodrigues AM
    J Diabetes Complications; 2024 Oct; 38(10):108834. PubMed ID: 39178623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management.
    Taha MB; Yahya T; Satish P; Laird R; Agatston AS; Cainzos-Achirica M; Patel KV; Nasir K
    Curr Atheroscler Rep; 2022 Aug; 24(8):643-654. PubMed ID: 35624390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonists and stroke: A systematic review and meta-analysis of cardiovascular outcome trials.
    Adamou A; Barkas F; Milionis H; Ntaios G
    Int J Stroke; 2024 Oct; 19(8):876-887. PubMed ID: 38676552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective.
    Jensterle M; Janez A; Fliers E; DeVries JH; Vrtacnik-Bokal E; Siegelaar SE
    Hum Reprod Update; 2019 Jul; 25(4):504-517. PubMed ID: 31260047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review and Meta-Analysis of the Safety and Efficacy of Using Glucagon-like Peptide-1 Receptor Agonists.
    Hu EH; Tsai ML; Lin Y; Chou TS; Chen TH
    Medicina (Kaunas); 2024 Feb; 60(3):. PubMed ID: 38541083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.
    Widiarti W; Sukmajaya AC; Nugraha D; Alkaff FF
    Diabetes Metab Syndr; 2021; 15(3):837-843. PubMed ID: 33866119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.